Abstract: The present invention relates to non-transgenic and transgenic plants, preferably crop plants, comprising at least one mutation of the KINTEOCHORE NULL2 (KNL2) protein, especially a mutation causing a substitution of an amino acid within the KNL2 protein, preferably within the C-terminal region of the KNL2 protein, which preferably have the biological activity of a haploid inducer. Further, the present invention provides methods of generating the plants of the present invention and haploid and double haploid plants obtainable by crossing the plants of the present invention with wildtype plants as well as methods of facilitating cytoplasm exchange.

Abstract: The present invention relates to a method for production of an oligomeric protein in eukaryotic cells by co-expression of two fusion proteins in eukaryotic cells comprising a protein-S-Tag fusion protein, wherein the protein is an antigen or an antibody, and a S-protein-tail piece (tp) fusion protein. Furthermore the present invention relates to an oligomeric protein comprising at least a protein-S-Tag fusion protein and a S-protein-tail piece (tp) fusion protein, wherein the protein of the protein-S-Tag fusion protein is an antigen or an antibody, and the use in vaccines.

Abstract: The present invention relates to nucleic acid molecules for use in inducing apomixis in a plant, transgenic cells, in particular transgenic plant cells, comprising said nucleic acid molecule, transgenic plants, in particular plant seeds, comprising said nucleic acid molecule, methods for inducing apomixis in a plant, methods for the production of apomictic plants and uses thereof.

Abstract: The present invention relates to nucleic acid molecules for use in inducing aponnixis in a plant, transgenic cells, in particular transgenic plant cells, comprising said nucleic acid molecule, transgenic plants, in particular plant seeds, comprising said nucleic acid molecule, methods for inducing apomixis in a plant, methods for the production of apomictic plants and uses thereof.

Abstract: The invention relates to promoter regions, under the control of which transgenes can be expressed in plants in an epidermis-specific and pathogen-inducible manner. The invention also relates to recombinant nucleic acid molecules, including the promoters, to transgenic plants and plant cells, transformed with said the nucleic acid molecules and to methods for producing the same. The invention also relates to nucleic acid molecules, including a promoter according to the invention, nucleic acid sequences or transgenes, which can convey resistance to pathogens, plants and cell plants, transformed with the nucleic acid molecules and methods for producing the same. The invention also relates to the use of the promoter region according to the invention for analyzing pathogen-induced signal transduction pathways in plant cells.

Abstract: The invention relates to methods of producing transgenic plants including pathogen resistant plants with recombinant nucleic acid molecules comprising promoter regions which provides expression of a desired transgene in epidermis-specific manner, and transgenic plants produced by said methods.

Abstract: The invention relates to promoter regions, under the control of which transgenes can be expressed in plants in an epidermis-specific and pathogen-inducible manner. The invention also relates to recombinant nucleic acid molecules, including said promoters, to transgenic plants and plant cells, transformed with said nucleic acid molecules and to methods for producing the same. Said invention also provides nucleic acid molecules, including a promoter according to the invention, nucleic acid sequences or transgenes, which can convey resistance to pathogens, plants and cell plants, transformed with said nucleic acid molecules and methods for producing the same. Said invention also relates to the use of the promoter region according to the invention for analyzing pathogen-induced signal transduction pathways in plant cells.

Abstract: The invention relates to a method for producing transgenic plants and/or plant cells having an elevated vitamin E content, said transgenic plants and/or plant cells having a serine-acetyltransferase (SAT) content and/or activity which is modified in relation to the wild type, and/or a modified thiol compound content. The invention also relates to the use of nucleic acids coding for a SAT, for producing transgenic plants or plant cells having an elevated vitamin E content. The invention further relates to a method for producing vitamin E by cultivating transgenic plants or plant cells having a modified SAT content in relation to the wild type.

Abstract: A set of a plurality of microsatellite markers is provided for plant species of the tribe Triticeae, particularly Triticum aestivum. Each of the markers are constituted by a sequence tagged site (STS) defined by two primers, specific to a particular microsatellite sequence. Each primer has an average length of 20±3 bases and flanks the particular microsatellite sequence. Each of the microsatellite markers is formed by amplification of the microsatellite sequence by a polymerase chain reaction, to form markers of different length.

Abstract: The present invention relates to new nucleic acid sequences, which code for a geranylgeranyl reductase, a method for producing new plants which contain the new DNA sequence and the content of tocopherol and/or chlorophyll of which is altered in comparison to wild-type plants, these new plants, parts and products thereof and plant cells as well as the use of the DNA sequences for the manipulation of tocopherol, chlorophyll and/or vitamin K1 content in transgenic plants, parts and products thereof and plant cells.

Abstract: The invention relates to cassettes for the expression of storable gene products in leaves and specifically in seeds, especially single-chain antibody fragments in leaves and seeds of transgenic tobacco and pea plants. The fields of application of the invention are biotechnology, medicine (diagnosis and therapy), foodstuffs and plant control and agriculture. The expression cassette of the invention comprises constitutive or seed-specific promoters, the LeB4 signal peptide, a gene to be expressed and an ER retention signal. Preference is given to an expression cassette containing the CaMV 35S promoter as the constitutive promoter, the gene for a single-chain antibody fragment as the gene and the amino acid sequence KDEL as the ER retention signal.

Abstract: The invention concerns embryonal (cardiomyocytary and cardiomyoblastary) cardiac muscle cells, their preparation and their use, in particular for cell-mediated gene transplant. The areas of application of the invention are medicine and genetic engineering. The embryonal cardiac muscle cells according to the invention contain two gene constructs comprising: a) a regulatory, 1.2-kb long DNA sequence of the ventricle-specific myosin light-chain-2 (MLC-2v) promoter, the selectable marker gene .beta.-galactosidase in fusion with the reporter gene neomycin; and b) a regulatory DNA sequence of the herpes simplex virus thymidine kinase promoter and the selectable marker gene hygromycin, and optionally immortalizing genes and/or optionally genes inactivated by homologous recombination and/or optionally one or a plurality of therapeutic genes.